Palladin (PALLD), a cytoskeletal protein encoded by the *PALLD* gene, plays critical roles in regulating cell morphology, motility, and adhesion. It interacts with actin filaments and other scaffolding proteins, maintaining structural integrity and facilitating dynamic cellular processes. PALLD is particularly important in tissues requiring high mechanical plasticity, such as during embryonic development, wound healing, and cancer metastasis. Dysregulation of PALLD expression has been linked to pathological conditions, including pancreatic cancer, breast cancer, and cardiovascular diseases, where aberrant cell migration or adhesion drives disease progression.
PALLD antibodies are essential tools for studying these mechanisms. They enable detection and localization of palladin isoforms (e.g., 90 kDa, 140 kDa) in cells and tissues via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to explore PALLD's role in tumor microenvironment remodeling, fibroblast activation, and epithelial-mesenchymal transition (EMT). Commercially available PALLD antibodies (e.g., from Abcam, Cell Signaling Technology) are often validated for specificity using knockout controls or siRNA silencing.
Recent studies highlight PALLD's potential as a biomarker for aggressive cancers or fibrosis. However, variability in isoform expression across tissues necessitates careful antibody selection and experimental validation. Ongoing research aims to clarify isoform-specific functions and therapeutic targeting opportunities, underscoring PALLD antibodies' continued relevance in cell biology and translational medicine.